CYBN:CC News and Press, CYBIN INC. From 05/09/23

Cybin (NEO: CYBN) (NYSE American: CYBN) , a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, has completed dosing in part b of its three-part CYB004-E phase 1 trial. The study is desi...

- Advancing to first-in-human dosing of CYB004, a proprietary deuterated DMT molecule - - CYB004 being developed to provide less invasive and more convenient dosing methods as compared with IV infused DMT - - Phase 1 topline data expected in Q3 2023 - Cybin Inc. ...

Cybin (NEO: CYBN) (NYSE American: CYBN) , a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, and its CEO Doug Drysdale will be spotlighted during the 26th annual Milken Institute Glob...

- CEO Doug Drysdale to speak on a mental health panel on May 2, 2023 - Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (“ Cybin ” or the “ Company ”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by deve...

Cybin (NYSE American: CYBN) (NEO: CYBN) , a clinical-stage biopharmaceutical company committed to revolutionizing mental health care by developing new and innovative psychedelic-based treatment options, today announced the launch of EMBARK Open Access. “EMBARK OA” is the first and o...

Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (“ Cybin ” or the “ Company ”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, today announced the laun...

Cybin (NYSE American: CYBN) (NEO: CYBN) , a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(R), today announced that its Chief Executive Officer Doug Drysdale will participate at the Oppenheimer 33rd Annual Health Care Conference taking place on March 13-15, 2023. Dr...

Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (“ Cybin ” or the “ Company ”), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics ® is pleased to announce that Doug Drysdale, Cybin’s Chief Executive Officer, will parti...

Cybin (NEO: CYBN) (NYSE American: CYBN) CEO Doug Drysdale and Chopra Foundation founder Deepak Chopra will be participating together on a panel at the upcoming South by Southwest(R) (SXSW) Conference; the title of the panel is “Open Minds: Innovations in Consciousness, Psychedelics &...

- Cybin CEO, Doug Drysdale and Wellness Icon Deepak Chopra to be featured on panel titled Open Minds: Innovations in Consciousness, Psychedelics & Mental Health - Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (“ Cybin ” or the “ Company ”), a bio...